GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals

More

  • Biotech's big outlook   Friday, 1 May 2015 | 2:09 PM ET
    Biotech's big outlook

    Corey Davis, Canaccord Genuity, says Gilead's earnings put a floor in the biotech space.

  • Are leveraged ETFs making biotech stocks sick? Friday, 1 May 2015 | 12:05 PM ET
    Biotech

    Jon Najarian, co-founder of OptionMonster.com, breaks down a worrisome trend in the stock market right now.

  • Unicorn plans to push diabetes drugs   Friday, 1 May 2015 | 11:17 AM ET
    Unicorn plans to push diabetes drugs

    Intarcia Therapeutics Inc. said it raised $225 million in the latest in a series of financing to support the development of its implantable drug-delivery pump for patients with diabetes.Kurt Graves, Intarcia Therapeutics chairman and CEO, discusses.

  • Pfizer mystery bidder for drugmaker Sobi: Sources Friday, 1 May 2015 | 8:31 AM ET
    People walk past Pfizer world headquarters in New York City.

    Pfizer is the bidder for Sobi, the disease specialist which disclosed that a potential buyer had made an offer, sources said.

  • Tough month for biotech   Friday, 1 May 2015 | 5:00 AM ET
    Tough month for biotech

    Carter Worth, head of technical analysis at Cornerstone Macro, talks U.S. stocks, including biotech, and what to expect in the month of May.

  • Gilead 1Q profit doubles on hepatitis C drug sales Thursday, 30 Apr 2015 | 6:02 PM ET
    An associate scientist at Gilead Sciences.

    Sales of the novel hepatitis C drugs Sovaldi and Harvoni helped the company top Wall Street estimates.

  • Biotech bunking together   Thursday, 30 Apr 2015 | 3:46 PM ET
    Biotech bunking together

    Biotech is bunking up in Cambridge's hottest zip codes as an affordable way to be in the hotbed of research. Details, with CNBC's Meg Tirrell.

  • Biotech land grab in Kendall Square   Thursday, 30 Apr 2015 | 2:56 PM ET
    Biotech companies expand in Kendall Square

    CNCB's Meg Tirrell reports on one of the biotechnology industry's capital cities. 130 life sciences companies occupy Kendall Square in Cambridge, Massachusetts.

  • Biotech boom land grab   Thursday, 30 Apr 2015 | 2:56 PM ET
    Biotech boom land grab

    Real estate in Kendall Square is exploding, where biotech and big pharma companies are finding homes. Joel Marcus, Alexandria Real Estate CEO, discusses what's driving the real estate boom in the area.

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Cost in health profile in US is not sustainable: Cigna CEO

    David Cordani, Cigna CEO, discusses Cigna's business strategy, the high price of drugs, and Obamacare.

  • Biotech's real estate boom   Thursday, 30 Apr 2015 | 6:23 AM ET
    Biotech's real estate boom

    CNBC's Meg Tirrell reports the boom in biotechnology is prompting a hunt for real estate in the Boston area, squeezing rents and forcing vacancy rates to historic lows.

  • Ariad CEO to retire in deal with activist Sarissa Wednesday, 29 Apr 2015 | 7:10 AM ET
    A chemist works in the lab of Ariad Pharmaceuticals.

    Ariad Pharmaceuticals' CEO will retire this year in a settlement with hedge fund Sarissa Capital, capping months of agitation.

  • Biogen takes on Alzheimer's   Tuesday, 28 Apr 2015 | 4:29 PM ET
    alzheimer's

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Optimism for the future of biotech Tuesday, 28 Apr 2015 | 4:27 PM ET
    Biotech

    The manager of Fidelity Biotech's portfolio is optimistic about the future of biotech as he sees a continuous attempt to innovate.

  • Reason to be optimistic in biotech: Pro   Tuesday, 28 Apr 2015 | 1:39 PM ET
    Reason to be optimistic in biotech: Pro

    Rajiv Kaul, Fidelity biotech portfolio manager, discusses long term investing and why he is optimistic about the biotech sector going forward.

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Celladon to cut jobs as gene therapy fails trial Monday, 27 Apr 2015 | 10:52 AM ET

    Celladon said it expected to cut jobs after the company's experimental gene therapy to treat heart failure failed a key trial.

  • Mylan/Perrigo, a more likely combination: Pro   Friday, 24 Apr 2015 | 1:16 PM ET
    Mylan/Perrigo, a more likely combination: Pro

    Fred Hassan, Warburg Pincus Partner and Managing Director, discusses the latest pharmaceutical deals making headlines and believes Mylan and Perrigo are the most complementary for a deal.

  • Mylan lowers price for Perrigo   Friday, 24 Apr 2015 | 10:37 AM ET
    Mylan lowers price for Perrigo

    CNBC's David Faber reports on pharmaceutical acquisitions making headlines including Mylan and Perrigo.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.